NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy.
NK:IO has raised $1.5M in total funding. The most recent round was Seed. The last funding was announced in July 2023.
NK:IO's investors include Parkwalk Advisors, Innovate UK, Future Planet Capital, the Imperial College Innovation Fund, UK Innovation & Science Seed Fund.
NK:IO is headquartered in London, United Kingdom.
NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy.
NK:IO is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NK:IO — Funding & Investors." VCBacked, July 25, 2023, https://www.vcbacked.co/company/nkio. Accessed July 20, 2026.
VCBacked. (2023). NK:IO — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/nkio
{{cite web |title=NK:IO — Funding & Investors |url=https://www.vcbacked.co/company/nkio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated